The pathobiology of
traumatic brain injury (TBI) includes activation of multiple
caspases followed by cell death with a spectrum of apoptotic phenotypes. There are initiator (e.g.
caspase-2, -8, and -9) and effector (e.g.
caspase-3 and -7)
caspases. Recently,
caspase-2 and -8 have been shown to regulate cell death via provoking
cytochrome c release from the mitochondria upstream of
caspase-9. Here, we show that an intracerebral injection of the pan-
caspase inhibitor
boc-Aspartyl(OMe)-fluoromethylketone (BAF; 1 micromol) 1 min after TBI in rats reduces caspase-3-like activity,
terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) and tissue damage, and
cytochrome c release in ipsilateral cortex at 24 h versus vehicle. To investigate whether either
caspase-2 and/or
caspase-8 activation may contribute to
cytochrome release, the effect of BAF treatment on
caspase-2 and
caspase-8 proteolysis was also examined.
boc-aspartyl(OMe)-fluoromethylketone treatment inhibited proteolysis of
caspase-2 but not
caspase-8 24 h after TBI in rats versus vehicle. However, BAF with or without
nerve growth factor (12.5 ng/h x 14 days intracerebrally via osmotic pump) did not result in differences in motor function, Morris water maze performance, hippocampal neuron survival, nor
contusion volume at 14 days. These data suggest that BAF treatment reduces acute cell death after TBI by inhibiting mitochondrial release of
cytochrome c, possibly via a mechanism involving
initiator caspases; however, BAF appears to delay cell death, rather than result in permanent protection.